Olaris Grows Leadership Team with Appointment of Dr. Stuart Chaffee as Executive Chairman
Summary
Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products is pleased to announce the appointment of Dr. Stuart Chaffee, a 20-year veteran in the biopharmaceutical industry, as Executive Chairman. In this new role for Olaris, Dr. Chaffee will partner with CEO Dr. Elizabeth O’Day and the Board of Directors to develop and execute strategic growth opportunities for the company. “Olaris’ pioneering metabolomic platform stands ready to deliver on its mission to dramatically improve our industry’s ability to accurately diagnose disease, identify the optimal therapies for treatment, and accurately monitor responses to those therapies.” Prior to joining Olaris, Chaffee was most recently Chief Business Officer at Affinivax, Inc., until its sale to GlaxoSmithKline in May of 2022. Prior to his time at Affinivax, Chaffee was Chief Business Officer and Chief Financial Officer at Praxis Precision Medicines, a clinical-stage genetic neuroscience company, where he raised over $100 million in private equity to fund an innovative pipeline identifying candidates for the development of novel therapies for patients affected by central nervous system disorders. As we continue to advance our myOLARIS products, his financial, strategic and operations expertise will be critical accelerators during this next stage of growth,” said Dr. Elizabeth O’Day, Chief Executive Officer and Founder.